[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334561-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334561-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","midterm-outcomes-of-transcatheter-aortic-valve-replacement-in-patients-with-active-cancer","Midterm outcomes of transcatheter aortic valve replacement in patients with active cancer","","Clinical outcomes of transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS) with concomitant active cancer remain insufficiently defined. Using the OCEAN-TAVI prospective Japanese registry, this study compared prognoses between patients with and without active cancer at TAVR. Among 2336 procedures (Oct 2013–Jul 2017), active cancer occurred in 89 patients, with lower 3-year survival (64.7% vs 74.7%), while limited-stage cancer showed no significant survival difference.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/midterm-outcomes-of-transcatheter-aortic-valve-replacement-in-patients-with-active-cancer/334561/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/midterm-outcomes-of-transcatheter-aortic-valve-replacement-in-patients-with-active-cancer/334561.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this study?","Question",{"text":63,"@type":64},"To assess the midterm outcomes of TAVR in patients diagnosed with aortic stenosis and active cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were outcomes compared between patients with and without active cancer?",{"text":68,"@type":64},"The study analyzed data from the OCEAN-TAVI prospective Japanese registry and compared prognoses and clinical outcomes at the time of TAVR.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about 3-year survival after TAVR?",{"text":72,"@type":64},"3-year survival was notably lower in patients with active cancer (64.7%) than in those without active cancer (74.7%), while limited-stage cancer (stage 1 or 2) did not significantly differ from patients without cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334561,1790880073,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Open access Valvular heart disease  \n Midterm outcomes of transcatheter  \naortic valve replacement in patients with active cancer  \nMasahiko Noguchi  ,1 Minoru Tabata,2,3 Joji Ito,2 Nahoko Kato,1 Kotaro Obunai,1 Hiroyuki Watanabe,1 Fumiaki Yashima  ,4 Yusuke Watanabe  ,5  \nToru Naganuma,6 Masahiro Yamawaki,7 Futoshi Yamanaka  ,8 Shinichi Shirai,9 Hiroshi Ueno,10 Norio Tada,11 Masanori Yamamoto  ,12,13 Kentaro Hayashida,14 on behalf of the OCEAN-TAVI investigators  \nTo cite: Noguchi M, Tabata M, Ito J, et al. Midterm outcomes of transcatheter aortic valve replacement in patients with active cancer. Open Heart 2024;11:e002573 . doi:10 . 1136/ openhrt-2023-002573  \nReceived 28 November 2023 Accepted 15 February 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Minoru Tabata;  \n[minorutabata@juntendo.ac.jp](minorutabata@juntendo.ac.jp)  \nABSTRACT  \nObjectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.  \nMethods Data from the OCEAN-TAVI, a prospective Japanese registry of TAVR procedures, was analysed to compare prognoses and clinical outcomes in patients with and without active cancer at the time of TAVR.  \nResults Of the 2336 patients who underwent TAVR from October 2013 to July 2017, 89 patients (3 .8%) had active cancer, whereas 2247 did not. Among patients with active cancer, 49 had limited-stage cancer (stage 1 or 2) . The prevalent cancers identified before TAVR were colon (21%), prostate (18%), lung (15%), liver (11%) and breast (9%) . Although the periprocedural complications and 30-day mortality rates were comparable between the groups, the 3-year survival rate after TAVR was notably lower inpatients with active cancer (64 .7%) than in those without active cancer (74 .7%; p=0 .016) . Nevertheless, the 3-year survival rate of patients with limited-stage cancer (stage 1 or 2) did not significantly differ from those without cancer (70 .6% vs 74 .7%, p=0 .50) .  \nConclusions The patients with active cancer exhibited significantly reduced midterm survival rates. However, no distinct disparity existed in those with limited-stage cancer (stage 1 or 2) . Although TAVR is a viable treatment in patients with AS with active cancer, the type and stage of cancer and prognosis should be carefully weighed in the decision-making process.  \nINTRODUCTION  \nCancer is the leading cause of death in Japan; the number of cases is increasing annually. The prevalence of aortic stenosis (AS) and cancer increases with age, and these conditions are often comorbid. Transcatheter aortic valve replacement (TAVR) has been established as the primary treatment modality for improving clinical outcomes in patients  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Transcatheter aortic valve replacement (TAVR) has been established as the primary treatment modality for improving clinical outcomes in patients with aortic stenosis (AS) at all surgical risks. However, patients with active cancer have been largely excluded from pivotal TAVR trials due to concerns about their relatively short and unpredictable life expectancies. Therefore, the clinical outcomes of TAVR in patients with AS and concomitant active cancer remain insufficiently explored.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ Based on a Japanese multicentre prospective registry, although patients with active cancer exhibited significantly reduced midterm survival rates, no distinct disparity exists in those with limited-stage cancer (stage 1 or 2) .\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ In the decision-making process, the decision to perform TAVR in patients with active cancer should b","cbCaiek9HfuxQRgC","https://ap.wps.com/l/cbCaiek9HfuxQRgC","pdf",999667,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Methods\n## Study population and design","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"To assess the midterm outcomes of TAVR in patients diagnosed with aortic stenosis and active cancer.\"},{\"question\":\"How were outcomes compared between patients with and without active cancer?\",\"answer\":\"The study analyzed data from the OCEAN-TAVI prospective Japanese registry and compared prognoses and clinical outcomes at the time of TAVR.\"},{\"question\":\"What did the study find about 3-year survival after TAVR?\",\"answer\":\"3-year survival was notably lower in patients with active cancer (64.7%) than in those without active cancer (74.7%), while limited-stage cancer (stage 1 or 2) did not significantly differ from patients without cancer.\"}]","Midterm outcomes of transcatheter aortic valve replacement in patients with active cancer | PDF",1790007211,18]